🇺🇸 FDA
Patent

US 11464764

Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

granted A61KA61K31/437A61K47/10

Quick answer

US patent 11464764 (Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound) held by Corcept Therapeutics Incorporated expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/437, A61K47/10, A61K47/14, A61K47/22